Ascendis Presents Updated and New TransCon IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26.10.2023 - —  Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy — TransCon IL-2 β⁄γ administered every ... Seite 1

Related Keywords

Copenhagen , Køavn , Denmark , Spain , Madrid , Stina Singel , Ascendis Pharma , Head Of Clinical Development , European Society Of Medical Oncology , Believe Trial , European Society , Medical Oncology , Executive Vice President , Clinical Development , Ascendis Pharma Chart , Scendis Pharma Kurs , Scendis Pharma Aktie ,